Global Cannabis Applications Corp. (“GCAC” or the “Company”)(GCAC) (CSE:APP, FRA:2FA, OTCQB:FUAPF), a leading developer of innovative data technologies for the cannabis industry, is pleased to announce that it has signed a Memorandum of Understanding (MOU) with One System One Solution (“OS2”) a joint venture of TheraCann International Benchmark Corporation (“TheraCann”) and TKS Ventures dba The Tokes Platform (“TKS”), to establish the infrastructure, technology and services required to create a sustainable supply chain and ecosystem for the cannabis industry. The parties will combine resources to provide software and services comprising a total solution for cultivators, distributors, medical patients & practitioners and regulators.

OS2 is building the world’s first fully integrated genetics-to-patient (fully seed-to-sale) Enterprise Relational Software Program (“ERP”), market place, commodity exchange & financial transaction compliance suite fully integrated with a blockchain. The ERP, previously known as the TheraCannSYSTEM, has been deployed as a Web based solution to support vertically integrated industrial cannabis cultivation, processing, packaging, quality assurance, and secure facilities around the world for over 5 years. Current client engagements include locations in Europe, North and South America and Australia. TKS Ventures owns and operates the Tokes Platform, a crypto-asset built on the WAVES blockchain that serves as a means for cannabis businesses to conduct commercial transactions.


OS2 will contribute the ERP (ISO 17025, 2005) and Safe Quality Food compliant Web based software. TKS will contribute expertise and talent related to cryptocurrency economic modelling, and access to the TKS Payment Gateway. TheraCann International will also contribute access and utilization of its patented Bio-Tagging tracking technology. GCAC will contribute its strain specific user and patient feedback, registry database, mobile applications, digital reward system for collecting user and clinical data and artificial intelligence algorithms.

“TheraCann has been providing our ERP solution to Cannabis cultivators around the world for 5 years, helping them improve return on investment, streamline cultivation and processing, improve quality and comply with local regulations, we partnered with TKS to add a cryptocurrency payment solution and full blockchain integration and are now developing a biometric tracking technology,” said Richard Goodman, President of OS2. “This MOU with GCAC adds the critical expertise and technology in collecting and using clinical and patient data with a cryptocurrency reward system.”

“Working with OS2 will accelerate the development of the Citizen Green Community. Together we will establish competitive advantages that position us to be the leader in providing a total solution to the growing global cannabis industry,” said Brad Moore, CEO of GCAC. “The MOU combined with our recently closed financing and addition of partners in the cryptocurrency space, provides GCAC with critical resources to implement our plans.”

About TheraCann International Benchmark Corporation

Founded in 2004, TheraCann International Benchmark Corporation offers a one-stop, full-service solution for the International cannabis marketplace. TheraCann provides business, technology and industry experts who apply advanced technology and help clients design, build and run their cannabis businesses. With nearly 3.5 million square feet of cannabis operations under management by 2019 and the successful launch of ground-breaking Enterprise Resource Planning (ERP) software, Aeroponic cultivation systems and patented genetic tracking and diversion prevention systems, TheraCann provides cannabis-related businesses with solutions to fit their regulatory requirements. More information about TheraCann is available at www.theracanncorp.com.

About Tokes Platform

The Tokes Platform is a digital currency and software development company focused on the legal cannabis industry. Tokes’ core initiatives include a blockchain-based e-payment solutions, industry agnostic point-of-sale software, as well as compliance and provenance management through a dedicated ERP seed-to-sale application. The ERP enables external developer integration through a modular design and improves regulatory compliance through transparency of payments and supply chain management. More details about the company available at www.tokesplatform.org

About Global Cannabis Applications Corp.

Global Cannabis Applications Corp. is a global leader in designing, developing, marketing and acquiring innovative data technologies for the cannabis industry. The Citizen Green platform is the world’s first end-to-end – from patient to regulator – medical cannabis data solution. It uses six core technologies: mobile applications, artificial intelligence, regtech, smart databases, blockchain and digital reward tokens, to qualify candidates for clinical studies. These technologies facilitate the proliferation of digital conversations by like-minded people in the medical cannabis community. Managed by digital and cannabis industry experts, GCAC is focused on viral global expansion by providing the best digital experience in the cannabis market.

For more information about the Company, please visit online at www.cannappscorp.com, or review its profiles www.sedar.com and on the Canadian Securities Exchange’s website (www.thecse.com).

To schedule an interview, please contact:

Bradley Moore

Chief Executive Officer

Telephone: 514-561-9091

Email: bmoore@cannappscorp.com

For more information, please contact:

Corporate Communications

Telephone: 1.855.269.9554

Email: info@cannappscorp.com

www.cannappscorp.com

Forward-Looking Information

This news release may include forward-looking information within the meaning of Canadian securities legislation, concerning the business of GCAC. Forward-looking information is based on certain key expectations and assumptions made by the management of GCAC. Although management of the Company believes that the expectations and assumptions on which such forward-looking information is based are reasonable, undue reliance should not be placed on the forward-looking information because GCAC can give no assurance that they will prove to be correct. Forward-looking statements contained in this news release are made as of the date of this news release. GCAC disclaims any intent or obligation to update publicly any forward-looking information, whether as a result of new information, future events or results or otherwise, other than as required by applicable securities laws.

The Canadian Securities Exchange has not reviewed and does not accept responsibility for the adequacy and accuracy of this information.

Click here to connect with Global Cannabis Applications Corp. and receive an Investor’s Presentation.

Source: www.thenewswire.com

/NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS/

Avicanna Inc. (the “ Company ” or “ Avicanna ”) (TSX: AVCN) (OTCQX: AVCNF) (FSE: 0NN) is pleased to announce that all of management’s nominees listed in the Company’s management information circular dated May 25, 2021 were elected as directors of the Company at Avicanna‘s annual general meeting of shareholders held on June 24, 2021 (the ” Meeting “). The detailed results of the vote for the election of directors held at the Meeting are set out below.

Keep reading... Show less

Quantum 1 Cannabis (CSE:QQ) announced its revenue for the third quarter of 2021 has increased by 672 percent and gross profit has increased by 463 percent compared with the same quarter in 2020. Quantum 1 Cannabis CEO Russ Rossi expounded on this exponential growth and what’s behind this remarkable leap. 

“We had an opportunity during our cannabis training to opt into some leases for cannabis retail. So we thought, let’s take a shot at this and see if we can use our experience with mobile location and supercharge. It paid off. It was a new game for everybody. It’s a lot of luck when opportunity meets preparation,” said Rossi. 

Quantum 1 Cannabis attributed the growth to high month-over-month sales coming from its flagship store in North Vancouver, improved demand for specialized “cottage-grown” sativa and indica products, continued training and hiring of best-of-breed staff and management to cater to consumer inquiries and expanded in-house technology for management of human resources, inventory and regulatory requirements. 

“Our plan is to have the maximum number of retail stores possible in British Columbia. We have 10 year leases on these stores, putting everything in on a solid pitch for the city council. I’m pretty confident that we’re going to have eight centers full blast in BC within six months,” explained Rossi. 

Quantum 1 Cannabis has signed a memorandum of understanding to acquire an approved municipal cannabis retail location in one of Vancouver’s most diverse neighborhoods at 41st Avenue and Cambie Street in Vancouver, British Columbia. The flagship location is expected to expand the company’s footprint in the Lower Mainland.

Watch the full interview with Quantum 1 Cannabis (CSE:QQ) CEO Russ Rossi above.

Keep reading... Show less

Process leads to standardized psychedelic extracts that are reproducible, scalable, cost-effective and commercially viable

Numinus Wellness Inc. (“Numinus” or the “Company”) (TSXV: NUMI), a mental health care company advancing innovative treatments and safe, evidence-based psychedelic-assisted therapies, is pleased to announce that its subsidiary Numinus Bioscience Inc. (“Numinus Bioscience”) has filed a provisional patent application with the United States Patent and Trademark Office (USPTO) for a process that dramatically increases the production of therapeutics for use in psychedelic-assisted psychotherapy.

Keep reading... Show less

Opening Marks Company’s 107th Retail Location Nationwide

Strategic Expansion Will Help Serve the State’s Rapidly Growing Cannabis Market

Keep reading... Show less

Ayurcann (CSE:AYUR) entered into a joint venture with Bazelet Group, Israel’s largest privately held medical cannabis company. Ayurcann CEO Igal Sudman shared the company’s excitement about bringing unique terpene-enriched medicinal cannabis to the Canadian marketplace. 

“Canada is a very closed-loop country, and the opportunity to bring a variety of different enhancement and technologically advanced products is very important to us. The relationship that we formed with Bazelet is going to enhance our offerings into the Canadian marketplace,” Sudman said. 

Bazelet has launched multiple lines of terpene-enriched cannabis oils; each one is specifically designed for various indications, symptoms and personal needs. The company’s terpene-enriched products are optimized for women’s health, for elderly population needs, for specific types of pains (muscle, joint, neuropathic) and for improved night sleep. 

According to Sudman, there are a lot of larger companies that have tried to do this, but none have been able to successfully bring innovation into the market. Ayurcann is rapidly forging partnerships with several companies worldwide, including Cannmart, Patient Choice and Kindred Partners.

“We’re growing the business, customer base, relationships and partnerships worldwide. We’re bringing the latest technology into Canada, and enhancing not only our company, but the investors’ value moving forward,” added Sudman. 

Watch the full interview with Ayurcann CEO Igal Sudman above.

Keep reading... Show less